Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
By S. Yusuf, K. Teo, C. Anderson, Janice Pogue, L. Dyal, I. Copland, H. Schumacher, Dagenais Gr, P. Sleight. The Lancet, 2008
890 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine
View Paper: https://www.semanticscholar.org/paper/a9062e9cfd64efb1bde90df128d3f3c7b37dc57e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- Douglas G. Altman
- David Moher
- G. Fonarow
- P. Gøtzsche
- K. F. Schulz
- Gerasimos Filippatos
- P. Devereaux
- Victor M. Montori
Citations in the corpus
- 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “Angiotensin receptor blockers are reasonable in other patients with cardiac or other vascular disease who are ACE inhibitor intolerant (139).”
- CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (2010, methodology): “Adapted from Table 1 of Yusuf et al [209].”
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. (2017, positive): “Long-term therapy with ARBs in patients with HFrEF produces hemodynamic, neurohormonal, and clinical effects consistent with those expected after interference with the renin-angiotensin system (145,146).”